



Living Cell Technologies Limited Company Announcement

Results of the General Meeting held on 7 June 2011

7 June 2011: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), the following voting results are in respect of the resolutions laid before Members at the General Meeting of Living Cell Technologies Ltd held today and is provided in accordance with ASX Listing Rule 3.13.2 and section 251AA (2) of the Corporations Act.

The total number of proxy votes exercisable by all proxies validly appointed was 80,696,902.

Resolution 1: Ratification of issue of 1,682,692 ordinary shares, 3,500,000 attaching options and A\$500,000 convertible securities pursuant to ASX Listing Rule 7.4

"That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 1,682,692 fully paid ordinary shares at an issue price of A\$0.1196 per share, 3,500,000 attaching options exercisable at A\$0.1989 per option and A\$500,000 of convertible securities, the details of which are set out in the explanatory notes to resolution 1 in the notice of this meeting."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
32,000,424	286,350	22,458,858	25,951,270

Resolution 2: Ratification of issue of 1,450,677 ordinary shares, pursuant to ASX Listing Rule 7.4

"That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 1,450,677 fully paid ordinary shares at an issue price of A\$0.10340, the details of which are set out in the explanatory notes to resolution 2 in the notice of this meeting."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
32,100,424	169,350	22,475,858	25,951,270

Resolution 3: Ratification of issue of 2,209,945 ordinary shares, pursuant to ASX Listing Rule 7.4

“That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 2,209,945 fully paid ordinary shares at an issue price of A\$0.09050, the details of which are set out in the explanatory notes to resolution 3 in the notice of this meeting.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
31,985,424	301,350	22,458,858	25,951,270

Resolution 4: Ratification of issue of 14,334,080 ordinary shares, pursuant to ASX Listing Rule 7.4

“That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 14,334,080 fully paid ordinary shares at an issue price of A\$0.12, the details of which are set out in the explanatory notes to resolution 4 in the notice of this meeting.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
54,543,282	201,350	14,335,080	11,617,190

Resolution 5: Ratification of issue of 19,000,000 ordinary shares and A\$720,000 convertible securities, pursuant to ASX Listing Rule 7.4

“That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 19,000,000 fully paid ordinary shares at an issue price of A\$0.12 per share and A\$720,000 of convertible securities, the details of which are set out in the explanatory notes to resolution 5 in the notice of this meeting.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
35,558,282	169,350	19,018,000	25,951,270

- Ends -

For further information: www.lctglobal.com

At the Company: Dr Ross Macdonald Managing Director Tel: +64 9 276 2690 rmacdonald@lctglobal.com Ms Susanne Clay Chief Business Officer, Living Cell Technologies Ltd. Tel: +64 9 270 7954 Mobile: +64 21 418 833 sclay@lctglobal.com	Media and investor enquiries: Buchan Consulting Rebecca Wilson Tel: +61 3 9866 4722 Mobile: +61 417 382 391 rwilson@bcg.com.au
--	--

About Living Cell Technologies - www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.